Peritoneal Dialysis Market

The key players, such as Fresenius Medical Care AG, Baxter International Inc., and Medtronic Plc, are enhancing their products for PD for better treatment. Baxter's Home Choice Claria System is a lightweight, portable PD cycler for APD use, with remote control. This will improve home PD use; the same program is provided by DaVita through its home kidney care services. In June 2023, Singapore General Hospital and AWAK Technologies have announced that a pre-pivotal clinical trial of an advanced version of the Automated Wearable Artificial Kidney Peritoneal Dialysis (AWAK PD) device has been launched. Based on its portability for dialysis, the FDA has given the company 'Breakthrough Device Designation'. In April 2023, the FDA granted Medtronic Plc approval of its Enlite Glucose Sensor, a device that aids in the improvement of continuous monitoring within PD treatments. In February 2023, the Innovation Fund of National Kidney Foundation funded Relavo, a developer of home dialysis through PeritoneX technology, which eliminates risk from infections through the sanitizing of dialysis tubes and minimizes the peritonitis rate. These R&D investments prove the industry's efforts toward promoting dialysis technologies, patient safety, and quality treatment for patients with kidney disease.

PD has several advantages over HD, but it is grossly underutilized worldwide, especially in LLMICs, where KRT is frequently unavailable, inaccessible, and unaffordable. Today, in the world, only 11% of dialysis patients are using PD; and more than 50% of them live in China, the US, Mexico, or Thailand. Reports across the world have revealed various types of barriers to increased PD utilization, including low levels of education and low reimbursements for providers. Some patients even prefer other modes of treatment over dialysis, which is a barrier as well. However, LLMICS also present unique yet surmountable challenges in the sense that they continue to pose very high and prohibitive costs of PD services, particularly fluids for PD; higher relative treatment cost to patients, compared to HD; lack of adequate PD training opportunities for healthcare staff; shortage of the kidney care workforce; and problems associated with some PD outcomes, such as catheter-related infections, hospitalizations, and mortality rates.

Consideration of emerging markets such as China, India, and Brazil will open up exceptional growth opportunities for players in the peritoneal dialysis market. It is because these markets are showing an increased prevalence of diabetes and CKD. Continued economic growth in China and India coincides with increased healthcare expenditure; hence, this enhances the affordability of peritoneal dialysis treatment. Regarding growth opportunities for ESRD, according to a 2023 article in BMC Nephrology, ESRD prevalence across China is projected to reach 1,505 patients per million population by 2025. To address the increasing demand for dialysis in the emerging market, the players aim to acquire or partner with healthcare providers. For instance, in December 2021, Baxter International Inc., a US company, made an acquisition of all outstanding equity interests of Hill-Rom Holdings, Inc., a global leader in medical technology. In April 2023, Medtronic and DaVita launched Mozarc Medical, an independent company that helps reshape kidney health by driving patient-centered tech solutions. Also, the rise in the number of dialysis clinics across emerging nations may also have an excellent growth prospect for the peritoneal dialysis market. Government initiatives, including increased investment in health infrastructure and subsidies for treatment costs across emerging economies to enhance access to healthcare services such as dialysis, are likely to expand market growth opportunities. The Government of India launched the Pradhan Mantri National Dialysis Programme (PMNDP), under which dialysis will be provided free of cost at the district hospitals across the country to BPL beneficiaries. Of the PMNDP beneficiaries up to 31 December 2022, about 1.7 million recipients were covered in terms of hemodialysis and peritoneal dialysis services

Low- and lower-middle-income countries (LLMICs) are experiencing an alarming shortage of skilled nephrologists, which has adversely affected kidney care services. The global median prevalence of nephrologists is 11.8 per million population, although this figure is highly variable across regions and income levels. Africa has the lowest count at 1.1 pRMR, while South Asia indicates a number as low as 1.8 pmp, followed by OSEA, at 3.2 pmp. Other countries in the list are likely to have the least percentage of nephrologists; they include Afghanistan at 0.03 PMP, Malawi at 0.05 PMP, and Mozambique at 0.09 PMP. A great number of countries also have no nephrologists present within them, and among such countries is Samoa, Solomon Islands, Vanuatu, and Andorra. Nephrologist trainees are also not spared, with LICS attaining a median prevalence as low as 0.1 pmp and LMICS reaching 0.3 pmp, whereas the figure was 1.3 Rmp in upper-middle-income countries (UMICs) and 3.9 pmp in high-income countries (HICs). In LICS, nephrologists shortfalls are very severe at 90%, and pediatric nephrologists shortfalls are severe at 95%. Shortfalls of transplant surgeons stay at 90%. Specialists who provide access to HD and PD are at100% and 90% respectively. These shortfalls are worse in the poorer regions where scarcity of training facilities and resources heightens the situation..